Rocket Lab's growing Space Systems business positions it to provide more than launches for the space economy. It generated $189.5M in Q2, 81% of revenue; if its pending Iridium acquisition closes, it would gain a global satellite communications network. At about $51, this is one of the most compelling long-term opportunities in the space sector over 3-5 years, provided it keeps executing. Neutron's launch has slipped to 2027, and execution risks remain. x.com  x.com  x.com 

Rocket Lab's defense contracts and backlog position it to benefit from national-security spending. Its $2.36B backlog includes over 100 booked launches, with an $816M SDA satellite deal and a $266M Space Force HASTE deal for hypersonic testing. Despite the Neutron delay, its $36B valuation offers one of the space sector's best risk-reward setups: exposure to the same defense and space-infrastructure trend as SpaceX at a fraction of its valuation. Rocket Lab is headed above $100. x.com 

Rocket Lab shares look set to grind as Neutron's first flight slips, even though the core business is at its strongest. Q2 revenue hit a record $234.1M, up 62%, and backlog rose 137% to $2.356B. But the Q3 guide cuts GAAP gross margin to 29-31% from 36.1%, below the ~37.6% expected, with adjusted EBITDA losses widening to $17-23M on low-margin satellite programs, Mynaric integration and Neutron spending. A Q1 2027 Neutron debut is now the base case, which will disappoint high expectations. x.com 

Rocket Lab's latest quarter supports a move toward $122, with growth, backlog and guidance all stepping up. Revenue cleared about $200M, up roughly 60% year over year, and backlog now exceeds $2B. Liquidity is strong, with about $1.5B in cash and more than $2B in total liquidity. Management again guided Q2 higher, to $232M versus a $208M street consensus. x.com 

Rocket Lab's expanding contracted work improves medium- and long-term revenue visibility. Synspective added 20 dedicated Electron launches for 2028-31, bringing its total to 47; backlog reached $2.4 billion after more than $1 billion in Q2 and early-Q3 awards. Space Systems broadens the business beyond launches, while Neutron's medium-lift upside still depends on reaching operational orbit. x.com 

Repeated Neutron delays undermine the premium on Rocket Lab stock when execution keeps slipping. The company does not live or die by Neutron, but 50x sales was unjustified; even at 26x 2027 sales, a legitimate price suggests another 50% decline. x.com  x.com 

Rocket Lab's after-hours selloff on a record quarter is a buying opportunity because it is becoming a space prime, one of only two full-stack space companies alongside SpaceX. Revenue hit a record $234M, up 62%, backlog a record $2.36B, up 137%, with more than $1B of Q3 contracts signed and $2.4B of cash. On VICTUS HAZE it launched in 16h42m against a 24-hour window. CEO Peter Beck said Neutron delay coverage is exaggerated. Rating stays Overweight with a $130 target. x.com  x.com  x.com 

Rocket Lab is set up for a breakout as its technicals and fundamentals align. A W-bottom is forming, with price bouncing off $64.6 support. Q2 revenue hit a record $234 million, up 62% year over year, and backlog rose 137% to an all-time high of $2.36 billion. It won a $397 million Space Force SB-AMTI contract to build and launch Flatellites on Neutron and joined the $981 million NITE-STAR contract ceiling, showing it is a vertically integrated space company, not just a launch provider. x.com 

Rocket Lab's delayed Neutron first flight pushes out a key part of its planned launch capacity. Flight one has moved to 2027, at least 1.5 years later than the previously indicated timing; the lack of clearer guidance is frustrating. The stock could fall 50% if it breaks key support, though that downside is conditional. x.com  x.com  x.com 

Rocket Lab's bounce has room to run to $65 after buyers returned following shipment of Neutron's second stage to its Virginia launch site. A break above $65 before November 9 results remains the real test. x.com